Pure Jamaican elevates Jamaica as a global provider of legal cannabis with pharmaceutical THC product exports to the U.S. and Brazil.
OG Article: here
View our Fair Use Policy: here
Pure Jamaican and its GMP-certified, licensed pharma manufacturer Seven-10 Pharmaceuticals are elevating Jamaica's role in the global cannabis supply chain by legally exporting proprietary pharmaceutical products with cannabis-derived THC, as well as hemp-derived CBD and other cannabinoids, to the United States, Brazil and other major international markets.
The permissions to export Pure Jamaican pharmaceutical products containing THC to the U.S. were granted by Jamaica's Ministry of Health and Wellness (MOHW) to Seven-10 Pharmaceuticals pursuant to valid corresponding import permits received from the U.S. Drug Enforcement Administration (DEA). The products were shipped to a DEA-licensed facility in the U.S. for successful analytical testing.
Once the DEA approves the rescheduling of THC from Schedule I to Schedule III under the U.S. Controlled Substance Act, as is widely anticipated, Seven-10 intends to request DEA permits to ship Pure Jamaican pharmaceutical THC products from Jamaica to patients in the U.S., subject to valid doctor prescriptions and all relevant DEA, Food and Drug Administration (FDA) and state pharmacy distribution regulations.
Meanwhile, Seven-10 has already begun shipping Pure Jamaican's Botanicos pharmaceutical tinctures with THC and other cannabinoids directly to patients in Brazil, pursuant to ANVISA import permits. Together, Brazil and the U.S. represent populations of more than 500 million people, providing tremendous potential demand.
Scott Cathcart, CEO of Pure Jamaican and Seven-10 Pharmaceuticals, said, "This is a proud moment for Jamaica and for our group of companies. Jamaica has long been associated with 'ganja' but never before in this context as a producer and legal exporter of THC as a pharmaceutical-grade medicine. As the only company in Jamaica licensed for pharmaceutical manufacturing of cannabinoids, we are proud to be leading the way to elevating the role of Jamaica in the global cannabis ecosystem."
The President of Jamaica Promotions Corp. (JAMPRO), Shullette Cox, said that "the growth of the cannabis industry for medicinal purposes has been a priority of the government of Jamaica and particularly, the export of value-added products from Jamaica. The success of Pure Jamaican and Seven-10 Pharmaceuticals is applauded as JAMPRO continues to facilitate the local medicinal cannabis industry and ensuring its role in driving the growth of exports."
Dr. Ellen Campbell Grizzle, chief regulatory and compliance officer of Pure Jamaican and Seven-10 Pharmaceuticals, and former dean of the College of Health Sciences, UTech, said, "This is a labor of love and not easy. Jamaica has 52 percent of the world's medicinal plants in our small island nation, and we are very proud to be exploring ways to identify new botanical medicines to bring health, wellness, new exports and economic growth to our country."
Comments